Andy Cohen said he used a small, doctor-supervised dose of a GLP-1 weight-loss medication over the summer and credited the treatment with helping him lose what he called a “good chunk of weight.” The 57-year-old Watch What Happens Live host discussed the regimen on his SiriusXM show, saying the therapy helped curb cravings and supported treatment for arterial plaque and high blood pressure.
Cohen said he "micro-dosed" the drug — taking a smaller portion than typical prescriptions — and did not name the specific medication. He described the approach as allowing him to avoid some of the unpleasant side effects commonly associated with GLP-1 medications, and said he stopped using the drug after reaching his weight-loss goal.
GLP-1 medications, which include well-known brand names such as Ozempic and Wegovy, act on hormones that regulate blood sugar and appetite by slowing stomach emptying and promoting a feeling of fullness. They have become widely discussed in recent years as celebrities and the general public have sought pharmaceutical assistance for weight loss. Cohen said the medication helped him resist post-drink snacking and workplace food temptations, which he described as a major contributor to his previous weight struggle.
"I was really unhappy with my weight," Cohen told listeners, adding that his doctor had recommended a GLP-1 several times before he agreed to try it. He said the drug "really helped me with cravings," allowing him to be "more disciplined with my diet and with working out." Cohen said his fitness regimen included lifting heavier weights and working with a trainer.
Cohen said he benefited from medical supervision and partial insurance coverage for the treatment, and described the medication as "revolutionary." He noted that without insurance such drugs can cost as much as $1,200 a month. He also said his appetite returned after he stopped micro-dosing but that the experience "caused me to reframe my relationship with food."
The host acknowledged the ethical impulse to disclose his experience. He said it would have been "completely hypocritical not to share" his weight-loss method, given that he frequently asks others about theirs and had lost a noticeable amount of weight.
Medical professionals say GLP-1 receptor agonists can be effective tools for weight management and glycemic control when prescribed and monitored by a physician, but they also caution about side effects such as nausea, bloating and diarrhea and emphasize that not all patients should use such drugs. Micro-dosing — taking smaller-than-standard doses — is an approach some patients and clinicians have explored to reduce side effects, though dosing strategies should be individualized and supervised by a healthcare provider.
Cohen's remarks come amid broader public conversation about the use of pharmaceutical approaches to weight loss in entertainment and wider society, where questions about access, cost and long-term medical supervision persist. He said he felt fortunate to have access to medical care and to have made changes under professional guidance before discontinuing the medication after meeting his objectives.